1） Swerdlow SH, Campo E, Harris NL, et al : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.
Revised 4th Edition, Lyon : International Agency for Research on Cancer, 2017
2） Kröger N, Giorgino T, Scott BL, et al : Impact of allogeneic stem cell transplantation on survival of patients less than
65 years of age with primary myelofibrosis. Blood 125 : 3347-3350 ; quiz 3364, 2015
3） Kroger NM, Deeg JH, Olavarria E, et al : Indication and management of allogeneic stem cell transplantation in primary
myelofibrosis. a consensus process by an EBMT/ELN international working group. Leukemia 29 : 2126-2133, 2015
4） Ali H, Bacigalupo A : 2021 Update on allogeneic hematopoietic stem cell transplant for myelofibrosis : A review of
400
Shinshu Med J Vol. 71
Dual-alkylator conditioning for MF
current data and applications on risk stratification and management. Am J Hematol 96 : 1532-1538, 2021
5） Sangle N, Cook J, Perkins S, et al : Myelofibrotic transformations of polycythemia vera and essential thrombocythemia
are morphologically, biologically, and prognostically indistinguishable from primary myelofibrosis. Appl Immunohistochem
Mol Morphol 22 : 663-668, 2014
6） Bacigalupo A, Innocenti I, Rossi E, et al : Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis : 2021.
Front Immunol 12 : 637512, 2021
7）
Kroger N, Sbianchi G, Sirait T, et al : Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after
allogeneic hematopoietic stem cell transplantation for myelofibrosis : a study of the CMWP of EBMT. Leukemia 35 :
3551-3560, 2021
8） 赤司浩一，下田和哉，桐戸啓太，他：骨髄線維症 診療の参照ガイド令和４年改訂版（第６版）
．In : Mitani K(ed) 特
発性造血障害疾患の診療の参照ガイド，2023
9） Tefferi A : Primary myelofibrosis : 2019 update on diagnosis, risk-stratification and management. Am J Hematol
93 : 1551-1560, 2018
10） McLornan D, Szydlo R, Koster L, et al : Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic
Stem Cell Transplantation in Myelofibrosis : A Retrospective Study by the Chronic Malignancies Working Party of
the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 25 : 2167-2171, 2019
11） Murata M, Nishida T, Taniguchi S, et al : Allogeneic transplantation for primary myelofibrosis with BM, peripheral
blood or umbilical cord blood : an analysis of the JSHCT. Bone Marrow Transplant 49 : 355-360, 2014
12） Deeg HJ, Bredeson C, Farnia S, et al : Hematopoietic Cell Transplantation as Curative Therapy for Patients with
Myelofibrosis : Long-Term Success in all Age Groups. Biol Blood Marrow Transplant 21 : 1883-1887, 2015
13） Martino R, Altés A, Muñiz-Díaz E, et al : Reduced transfusion requirements in a splenectomized patient undergoing
bone marrow transplantation. Acta Haematologica 92 : 167-168, 1994
14） Cervantes F, Dupriez B, Pereira A, et al : New prognostic scoring system for primary myelofibrosis based on a
study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113 : 2895-2901, 2009
15） Chiusolo P, Bregante S, Giammarco S, et al : Full donor chimerism after allogeneic hematopoietic stem cells transplant
for myelofibrosis : The role of the conditioning regimen. Am J Hematol 96 : 234-240, 2021
16）
Bregante S, Dominietto A, Ghiso A, et al : Improved Outcome of Alternative Donor Transplantations in Patients with
Myelofibrosis : From Unrelated to Haploidentical Family Donors. Biol Blood Marrow Transplant 22 : 324-329, 2016
17）
Memoli M, Paviglianiti A, Malard F, et al : Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with
myelofibrosis undergoing allogeneic hematopoietic transplantation : a single center experience. Leuk Lymphoma
62 : 419-427, 2021
18） Yamamoto H, Uchida N, Matsuno N, et al : I.v. BU/fludarabine plus melphalan or TBI in unrelated cord blood
transplantation for high-risk hematological diseases. Bone Marrow Transplant 50 : 607-609, 2015
19）
Yamamoto H, Uchida N, Yuasa M, et al : A Novel Reduced-Toxicity Myeloablative Conditioning Regimen Using
Full-Dose Busulfan, Fludarabine, and Melphalan for Single Cord Blood Transplantation Provides Durable Engraftment
and Remission in Nonremission Myeloid Malignancies. Biol Blood Marrow Transplant 22 : 1844-1850, 2016
20） Ueda T, Jo T, Okada K, et al : Curative potential of fludarabine, melphalan, and non-myeloablative dosage of busulfan
in elderly patients with myeloid malignancy. Int J Hematol 111 : 247-255, 2020
21） Ueda T, Maeda T, Kusakabe S, et al : Addition of melphalan to fludarabine/busulfan (FLU/BU4/MEL) provides
survival benefit for patients with myeloid malignancy following allogeneic bone-marrow transplantation/peripheral
blood stem-cell transplantation. Int J Hematol 109 : 197-205, 2019
22） Takagi S, Ota Y, Uchida N, et al : Successful engraftment after reduced-intensity umbilical cord blood transplantation
for myelofibrosis. Blood 116 : 649-652, 2010
23） Passamonti F, Cervantes F, Vannucchi AM, et al : Dynamic International Prognostic Scoring System (DIPSS) predicts
No. 6, 2023
401
Asai・Matsuzawa・Kawakami et al.
progression to acute myeloid leukemia in primary myelofibrosis. Blood 116 : 2857-2858, 2010
24） Gangat N, Caramazza D, Vaidya R, et al : DIPSS plus : a refined Dynamic International Prognostic Scoring System
for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion
status. J Clin Oncol 29 : 392-397, 2011
25） Passamonti F, Giorgino T, Mora B, et al : A clinical-molecular prognostic model to predict survival in patients with
post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia 31 : 2726-2731, 2017
26）
Kucybala I, Ciuk S, Teczar J : Spleen enlargement assessment using computed tomography : which coefficient
correlates the strongest with the real volume of the spleen? Abdom Radiol (NY) 43 : 2455-2461, 2018
27） Matsuda K, Yamauchi K, Tozuka M, et al : Monitoring of hematopoietic chimerism by short tandem repeats, and the
effect of CD selection on its sensitivity. Clin Chem 50 : 2411-2414, 2004
28） Kharfan-Dabaja MA, Kumar A, Ayala E, et al : Standardizing Definitions of Hematopoietic Recovery, Graft Rejection,
Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation : A
Report on Behalf of the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther 27 : 642649, 2021
29） Kanda Y : Investigation of the freely available easy-to-use software ’EZR’ for medical statistics. Bone Marrow
Transplant 48 : 452-458, 2013
30）
Hussein K, Stucki-Koch A, Alchalby H, Triviai I, Kroger N, Kreipe H : Cytokine Expression Pattern in Bone Marrow
Microenvironment after Allogeneic Stem Cell Transplantation in Primary Myelofibrosis. Biol Blood Marrow Transplant
22 : 644-650, 2016
31） Bognàr T, Bartelink IH, Egberts TCG, et al : Association Between the Magnitude of Intravenous Busulfan Exposure
and Development of Hepatic Veno-Occlusive Disease in Children and Young Adults Undergoing Myeloablative
Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther 28 : 196-202, 2022
32） Strouse C, Zhang Y, Zhang MJ, et al : Risk Score for the Development of Veno-Occlusive Disease after Allogeneic
Hematopoietic Cell Transplant. Biol Blood Marrow Transplant 24 : 2072-2080, 2018
33）
Shouval R, Vega Y, Fein JA, et al : Allogeneic hematopoietic stem cell transplantation with fludarabine, busulfan, and
thiotepa conditioning is associated with favorable outcomes in myelofibrosis. Bone Marrow Transplant 55 : 147-156,
2020
（2023. 5. 12 received ; 2023. 8. 21 accepted） 402
Shinshu Med J Vol. 71
...
論文の公開元へ
